Concepedia

Author

Christoph Wandel

Roche (United Kingdom)

Also Known As

C WANDEL, C Wandel, C. WANDEL, C. Wandel, Christoph Wandel, Wandel, Christoph

64

Publications

2.3K

Citations

19

H-Index

43

Concepts

All Affiliations

Roche (United Kingdom)Roche (Switzerland)Vanderbilt UniversityHeidelberg UniversityWashington University in St. Louis
CW

About

Christoph Wandel is an author at Roche (United Kingdom) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

563

2

Anesthesia

2

2

53

3

Biochemistry

2

2

409

4

Engineering

1

1

18

5

Natural Sciences

1

1

254

Christoph Wandel

×

25

Publications

2.2K

Citations

19

H-Index

YearCitations

Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein

Richard B. Kirn, Christoph Wandel, Brenda F. Leake,

Pharmaceutical Research

1999

459

P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.

Christoph Wandel, Richard B. Kim, Shama Kajiji,

PubMed

1999

254

CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promoter region polymorphism

Christoph Wandel

Clinical Pharmacology & Therapeutics

2000

247

Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein

Christoph Wandel, Richard Kim, Margaret Wood,

Anesthesiology

2002

213

Midazolam is metabolized by at least three different cytochrome P450 enzymes

Christoph Wandel, R. Böcker, H. Böhrer,

British Journal of Anaesthesia

1994

155

Morbidity and medication in a large population of individuals with Down syndrome compared to the general population

M Alexander, H. Petri, Yingjie Ding,

Developmental Medicine & Child Neurology

2015

139

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

Federico Bolognani, Marta del Valle Rubido, Lisa Squassante,

Science Translational Medicine

2019

120

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial

Jerry R. Mendell, Francesco Muntoni, Craig M. McDonald,

Nature Medicine

2024

116

Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to &lt;8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study <scp>SRP</scp>‐9001‐103 (<scp>ENDEAVOR</scp>)

Craig M. Zaidman, Crystal M. Proud, Craig M. McDonald,

Annals of Neurology

2023

83

Recovery characteristics following anaesthesia with sevoflurane or propofol in adults undergoing out-patient surgery

Christoph Wandel, S. P. W. Neff, H. B�hrer,

European Journal of Clinical Pharmacology

1995

42

Page 1